Prevention and treatment of murine experimental allergic encephalomyelitis with T cell receptor Vβ-specific antibodies
Experimental allergic encephalomyelitis (EAE) is a model system for T cell-mediated autoimmune disease. Symptoms of EAE are similar to those of multiple sclerosis (MS) in humans. EAE is induced in susceptible animal strains by immunization with myelin basic protein (MBP) and potent adjuvant. The major T cell response to MBP in B10.PL mice is directed towards an NH2-terminal epitope and involves T cells expressing either V beta 8.2 or V beta 13 gene segments. Animals treated with a TCR V beta 8-specific mAb have a reduced incidence of EAE. We report here that the in vivo administration of a combination of anti-V beta 8.2 and anti-V beta 13 mAbs results in a long-term elimination of T cells involved in the response to MBP. When given before MBP immunization, anti-TCR antibody treatment leads to nearly complete protection against EAE. Antibody treatment also results in a dramatic reversal of paralysis in diseased animals. Thus, treatment with a combination of V beta-specific antibodies is a very effective therapy for the prevention and treatment of EAE. It is hoped that the future characterization of TCR V gene usage in human autoimmune diseases may lead to similar strategies of immune intervention.
Additional Information© 1990 by Rockefeller University Press. RUP grants the public the non-exclusive right to copy, distribute, or display the Work under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/ and http://creativecommons.org/licenses/by-nc-sa/3.0/legalcode. Received for publication 9 February 1990. We thank Rochelle A. Diamond and Patrick F. Koen for expert technical assistance with the flow cytometry, and Eef Goedemans and Anita Ackerman for animal care. We also thank Deborah Nickerson and Joan Goverman for a critical reading of the manuscript. This work was supported by the Seaver Foundation and T Cell Sciences, Inc. D. M. Zaller is a recipient of the Cancer Research Institute/Miriam and Benedict Wolf Fellowship.
Published - ZALjem90.pdf